View details of this raise on Seedstage

Boston, MA

Building an at-home molecular diagnostic platform and test-to-treat workflow, starting with strep, to accelerate care for time-sensitive infections.

• Manufacturing and device readiness: Proceeds support final device design for manufacturability and selection of contract manufacturing partners.
• Clinical validation and evidence build: Funding is allocated to complete pre-clinical work and set up pivotal validation studies.
• Regulatory pre-submission work: The plan includes regulatory engagement and preparation of a pre-submission package.
• Test-to-treat workflow integration: Resources are directed to connect scan results with telehealth confirmation and pharmacy delivery for treatment.
• Strep-first platform expansion: The company starts with an at-home molecular strep test while designing a pathway to expand the platform to additional infections.

Anywhere Dx is raising capital to finalize device design for manufacturability, lock in contract manufacturing partners, complete pre-clinical work and pivotal validation studies, and prepare regulatory submission materials. Proceeds also fund regulatory engagement and the development of a test-to-treat workflow that links test scanning to telehealth and pharmacy delivery.

The company builds at-home, lab-quality diagnostics for time-sensitive infections, starting with strep. A palm-sized, instrument-free molecular test uses a saliva swab and a disposable workflow with a visual molecular readout, aiming to deliver symptom-to-care guidance in under an hour. Results are intended to trigger telehealth confirmation and prescription routing through an integrated digital flow. Rather than operating as a single assay, Anywhere Dx plans to expand the platform across additional high-frequency infections such as UTIs, STIs, and respiratory pathogens. Existing efforts include a working prototype showing lab-quality performance targets and non-dilutive validation support from NSF and NIH. Strep is used as an initial target because of high frequency and the potential for complications when treatment is delayed. The design also emphasizes usability for families and care teams, reducing reliance on clinic-based sample processing and wait times. This funding is meant to move from prototype readiness to scalable manufacturing and clinical evidence while strengthening the connected pathway from testing to treatment in near-patient and home settings.

Company Info

Anywhere Dx develops an at-home, instrument-free molecular diagnostic platform for time-sensitive infections, starting with at-home strep testing and a connected test-to-treatment workflow.

Anywhere Dx creates at-home diagnostic tools for time-sensitive infections, beginning with strep. The company focuses on lab-quality molecular testing designed to deliver high sensitivity and specificity using an instrument-free, disposable format suitable for consumer use. Results are intended to be obtained quickly at home, with a simple sample-to-readout experience.

The platform is built as a complete test-to-treatment workflow. A user runs the test at home, scans or records the result, and then connects to telehealth for clinical interpretation and prescription if appropriate. The underlying approach is designed to support expansion from strep to additional infections, with the same user experience and technology framework adapted across a broader assay menu.